NS
Nirav Sureshbhai Shah
About Nirav Sureshbhai Shah
Data last updated:
Nirav Sureshbhai Shah has 8 years in corporate governance. Holds Designated Partner and Director roles. Currently with 6 companies, including Synetech Lifescience Llp and Synetech Pharma Drugs Private Limited. Engaged in Technology, General Business. Contributes to corporate operations.
Current companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
 Synetech Lifescience Llp AAW-0534 | Designated Partner | 25 Feb 2021 | 2021 | Active |
| Synetech Pharma Drugs Private Limited U24100GJ2020PTC113199 | Director | 05 Mar 2021 | 2020 | Active |
| Synex Global Alliance Llp AAO-5312 | Designated Partner | 13 Mar 2019 | 2019 | Active |
 Synex Global Services Llp AAK-8738 | Designated Partner | 16 Oct 2017 | 2017 | Active |
| Synex Global Enterprises Llp ACT-0728 | Designated Partner | 28 Nov 2025 | 2025 | Active |
| German Freight Terminal Llp ACF-4807 | Designated Partner | 11 Feb 2024 | 2024 | Active |
Previous companies
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Nirav Sureshbhai Shah
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nirav Sureshbhai Shah
Nirav Sureshbhai Shah has 8 years in corporate governance. Holds Designated Partner and Director roles. Currently with 6 companies, including Synetech Lifescience Llp and Synetech Pharma Drugs Private Limited. Engaged in Technology, General Business. Contributes to corporate operations.
Nirav Sureshbhai Shah is associated with 6 companies as Designated Partner and Director.
Nirav Sureshbhai Shah has expertise in Technology, General Business.
Nirav Sureshbhai Shah has 8 years in corporate governance.